Some of the challenges in drug development for irritable bowel syndrome
Open Access
- 1 May 2001
- Vol. 48 (5) , 585-586
- https://doi.org/10.1136/gut.48.5.585
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Effects of octreotide on responses to colorectal distension in the ratGut, 2001
- Visceral hypersensitivity: facts, speculations, and challengesGut, 2001
- Effects of kappa opioids in the inflamed rat colonPain, 1999
- The κ agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndromeGastroenterology, 1999
- Is rectal pain sensitivity a biological marker for irritable bowel syndrome: Psychological influences on pain perceptionGastroenterology, 1998
- Effect of alosetron on responses to colonic distension in patients with irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 1998
- Somatostatin receptors in the central nervous systemProgress in Neurobiology, 1996
- Intrathecal Octreotide for Relief of Intractable Nonmalignant Pain: 5-Year Experience with Two CasesNeurosurgery, 1996
- Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle toneDigestive Diseases and Sciences, 1994
- Octreotide: a potent new non-opiate analgesic for intrathecal infusionPain, 1992